Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at ...

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, ...

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break ...

Video content above is prompted by the following: This segment introduces a comprehensive case study of a 46-year-old graphic designer diagnosed with stage IV NSCLC harboring an EGFR exon 19 deletion ...

Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy. The FDA has granted acceleratedapproval to the antibody ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.